Core Insights - The State Street SPDR S&P Biotech ETF (XBI) is a passively managed ETF launched on January 31, 2006, designed to provide broad exposure to the Healthcare - Biotech segment of the equity market [1] - The ETF has gained popularity among retail and institutional investors due to its low costs, transparency, flexibility, and tax efficiency [1][2] - As of now, the fund has amassed over $7.82 billion in assets, making it one of the largest ETFs in the Healthcare - Biotech sector [3] Index and Performance - XBI seeks to match the performance of the S&P Biotechnology Select Industry Index, which represents the biotechnology sub-industry portion of the S&P Total Markets Index [4] - The ETF has shown a performance increase of approximately 35.52% over the past year and about 28.8% year-to-date [8] - The ETF has a beta of 0.87 and a standard deviation of 26.86% over the trailing three-year period, indicating a high-risk profile [8] Costs and Holdings - The annual operating expense ratio for XBI is 0.35%, making it one of the least expensive options in the ETF space [5] - The ETF has a 12-month trailing dividend yield of 0.03% [5] - The fund is fully allocated to the Healthcare sector, with Crispr Therapeutics Ag (CRSP) accounting for about 2.48% of total assets, and the top 10 holdings representing approximately 19.54% of total assets [6][7] Alternatives - XBI carries a Zacks ETF Rank of 3 (Hold), indicating it is a sufficient option for investors seeking exposure to the Health Care ETFs area [9] - Other ETF options in the space include First Trust NYSE Arca Biotechnology ETF (FBT) with $1.35 billion in assets and iShares Biotechnology ETF (IBB) with $8.60 billion in assets, both having higher expense ratios than XBI [10]

Core Insights - The State Street SPDR S&P Biotech ETF (XBI) debuted on January 31, 2006, and provides broad exposure to the Health Care ETFs category [1] - XBI is a smart beta ETF that aims to outperform the market through non-cap weighted strategies [3][4] - The fund is managed by State Street Investment Management and has amassed over $7.49 billion in assets, making it one of the largest ETFs in the Health Care sector [5] Fund Structure - XBI seeks to match the performance of the S&P Biotechnology Select Industry Index, which represents the biotechnology sub-industry of the S&P Total Markets Index [6] - The ETF has an annual operating expense ratio of 0.35%, making it one of the least expensive options in its category [7] - The fund is fully allocated to the Healthcare sector, with its top 10 holdings accounting for approximately 19.54% of total assets [8][9] Performance Metrics - As of November 19, 2025, XBI has gained about 27.94% and is up approximately 25.3% year-to-date [11] - The ETF has traded between $69.80 and $115.18 over the past 52 weeks, with a beta of 0.95 and a standard deviation of 27.12% for the trailing three-year period [11] Alternatives - Other ETFs in the biotechnology space include the First Trust NYSE Arca Biotechnology ETF (FBT) and the iShares Biotechnology ETF (IBB), with assets of $1.24 billion and $7.56 billion respectively [13] - FBT has an expense ratio of 0.54%, while IBB charges 0.44%, providing investors with alternative options [13]

Market Performance - Wall Street experienced poor performance in the last trading session, with SPY slipping 0.9%, DIA tumbling 1.2%, and QQQ moving 0.9% lower [1] ETF Trading Volumes - Two specialized ETFs showed significant trading volumes, exceeding normal levels, with both experiencing volumes more than double their average [1] Invesco Biotechnology & Genome ETF (PBE) - PBE had a trading volume of 20,471 shares, which is 4.03 times its average of 5,075 shares, and it lost about 0.3% in the last session while gaining 6.1% over the past month [2] First Trust NYSE Arca Biotechnology ETF (FBT) - FBT saw around 89,466 shares traded, which is 4.12 times its average of 21,699 shares, and it inched up 0.2% in the last session, with a gain of 5.7% over the past month [3]

Core Viewpoint - The First Trust NYSE Arca Biotechnology ETF (FBT) provides broad exposure to the Healthcare - Biotech segment, appealing to both institutional and retail investors due to its low cost and transparency [1][2]. Group 1: ETF Overview - FBT is a passively managed ETF launched on June 19, 2006, with assets exceeding $1.08 billion, making it one of the larger ETFs in the Healthcare - Biotech sector [1][3]. - The ETF aims to match the performance of the NYSE Arca Biotechnology Index, which is an equal dollar weighted index measuring the performance of biotechnology companies [3][4]. Group 2: Costs and Performance - The annual operating expense ratio for FBT is 0.54%, which is competitive within its peer group, and it has a 12-month trailing dividend yield of 0.67% [5]. - As of August 18, 2025, FBT has increased by approximately 4.88% year-to-date and 4.32% over the past year, with a trading range between $145.666 and $182.19 in the last 52 weeks [8]. Group 3: Sector Exposure and Holdings - FBT has a 100% allocation in the Healthcare sector, with Acadia Pharmaceuticals Inc. (ACAD) representing about 4.41% of total assets, and the top 10 holdings accounting for approximately 39.27% of total assets [6][7]. Group 4: Alternatives and Market Position - FBT carries a Zacks ETF Rank of 3 (Hold), indicating it is a reasonable option for investors seeking exposure to the Healthcare ETFs market [9]. - Other alternatives in the space include SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB), with assets of $5.09 billion and $5.63 billion respectively, and lower expense ratios of 0.35% and 0.45% [10].

Core Insights - The iShares Biotechnology ETF (IBB) is a smart beta ETF that provides broad exposure to the Health Care ETFs category, having debuted on February 5, 2001 [1] - Smart beta ETFs are designed to outperform traditional market cap weighted indexes by focusing on specific fundamental characteristics [3][4] - IBB is managed by Blackrock and has over $5.63 billion in assets, making it one of the largest ETFs in the Health Care sector [5] Fund Details - IBB aims to match the performance of the Nasdaq Biotechnology Index, which includes securities of NASDAQ listed biotechnology and pharmaceutical companies [5] - The fund has an annual operating expense of 0.45% and a 12-month trailing dividend yield of 0.28% [6] - The fund's portfolio is entirely allocated to the Healthcare sector, with Vertex Pharmaceuticals Inc (VRTX) being the largest holding at approximately 7.96% of total assets [7][8] Performance Metrics - As of August 18, 2025, IBB has returned approximately 5.05% year-to-date but is down about -4.01% over the past year [10] - The fund has traded between $112.02 and $149.47 in the last 52 weeks, with a beta of 0.75 and a standard deviation of 20.16% over the trailing three-year period, indicating a higher risk profile [10] Alternatives - Other ETFs in the biotechnology space include the First Trust NYSE Arca Biotechnology ETF (FBT) and the SPDR S&P Biotech ETF (XBI), with assets of $1.08 billion and $5.09 billion respectively [12] - FBT has an expense ratio of 0.54% while XBI charges 0.35%, presenting lower-cost alternatives for investors [12]

Core Viewpoint - The iShares Biotechnology ETF (IBB) is a prominent option for investors seeking exposure to the Healthcare - Biotech segment, offering low costs, transparency, and tax efficiency [1][2]. Group 1: Fund Overview - IBB is a passively managed ETF launched on February 5, 2001, with assets exceeding $5.47 billion, making it one of the largest in its category [3]. - The fund aims to match the performance of the Nasdaq Biotechnology Index, which includes securities from NASDAQ-listed biotechnology and pharmaceutical companies [3]. Group 2: Costs and Performance - The annual operating expense ratio for IBB is 0.45%, which is competitive within its peer group, and it has a 12-month trailing dividend yield of 0.29% [4]. - Year-to-date, IBB has gained approximately 1.45% but is down about 5.07% over the past year, with a trading range between $112.02 and $149.47 in the last 52 weeks [7]. Group 3: Sector Exposure and Holdings - IBB has a 100% allocation in the Healthcare sector, providing diversified exposure to minimize single stock risk [5]. - The top holdings include Vertex Pharmaceuticals Inc (7.96%), Amgen Inc, and Gilead Sciences Inc, with the top 10 holdings representing about 47.73% of total assets [6]. Group 4: Risk and Alternatives - The ETF has a beta of 0.75 and a standard deviation of 20.16% over the trailing three-year period, indicating a higher risk profile [7]. - Alternatives to IBB include the First Trust NYSE Arca Biotechnology ETF (FBT) and the SPDR S&P Biotech ETF (XBI), with respective assets of $1.03 billion and $4.65 billion [9].

Core Insights - The SPDR S&P Biotech ETF (XBI) is a smart beta ETF launched on January 31, 2006, providing broad exposure to the Health Care ETFs category [1] - XBI is managed by State Street Global Advisors and has over $5.04 billion in assets, making it one of the largest ETFs in the Health Care sector [5] - The ETF aims to match the performance of the S&P Biotechnology Select Industry Index, which is a modified equal weight index representing the biotechnology sub-industry [6] Investment Strategy - Smart beta ETFs like XBI focus on non-cap weighted strategies, selecting stocks based on fundamental characteristics to enhance risk-return performance [3] - The ETF has an annual operating expense ratio of 0.35%, making it one of the least expensive options in its category [7] Sector Exposure and Holdings - XBI's portfolio is entirely allocated to the Healthcare sector, with Insmed Inc (INSM) being the largest holding at approximately 3.29% of total assets [8][9] - The top 10 holdings of XBI account for about 27.56% of its total assets under management [9] Performance Metrics - Year-to-date, XBI has experienced a loss of approximately -2.42%, and over the last 12 months, it is down about -6.86% [11] - The ETF has a beta of 0.86 and a standard deviation of 29.73% over the trailing three-year period, indicating a higher risk profile [11] Alternatives - Other ETFs in the biotechnology space include the First Trust NYSE Arca Biotechnology ETF (FBT) and the iShares Biotechnology ETF (IBB), with assets of $1.03 billion and $5.52 billion respectively [13] - FBT has an expense ratio of 0.54%, while IBB charges 0.45%, providing investors with alternative options [13]